Merck to discontinue bacterial infection drug Zinplava
Merck will discontinue its antibody-drug Zinplava for a bacterial infection that can lead to fatal diarrhea, according to the U.S. Food and Drug Administration's website.
Zinplava, first approved by the regulator in 2016 for prevention of the recurrence of Clostridioides difficile infections (CDI), a bacterial infection often caused by prolonged use of antibiotics. CDI can lead to potentially fatal diarrhea and inflammation of the colon.
The FDA’s website states that the discontinuation of Zinplava will take effect on January 31, but no reason was cited for this decision.
The drugmaker did not immediately comment on the matter, Reuters reported.
Medical Dialogues team had earlier reported that the Company had announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab was being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA ) in the KeyVibe program. Favezelimab was being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
Next Story